Fecal incontinence after prostate cancer irradiation: a systematic literature review <p>Prostate Cancer and Prostatic Diseases, Published online: 02 February 2026; <a href="https://www.nature.com/articles/s41391-026-01078-8">doi:10.1038/s41391-026-01078-8</a></p>Fecal incontinence after prostate cancer irradiation: a systematic literature review Prostate Cancer Journal February 4, 2026 Original source
Comparative diagnostic accuracy of multiparametric-MRI and Micro-ultrasound for clinically significant prostate cancer—a bivariate meta-analysis of prospective studies <p>Prostate Cancer and Prostatic Diseases, Published online: 03 February 2026; <a href="https://www.nature.com/articles/s41391-026-01079-7">doi:10.1038/s41391-026-01079-7</a></p>Comparative diagnostic accuracy of multiparametric-MRI and Micro-ultrasound for clinically significant prostate cancer—a bivariate meta-analysis of prospective studies Prostate Cancer Journal February 4, 2026 Original source
Bridging the gap between PSMA-PET and reality: critical missing elements in AR-guided pelvic lymph node dissection <p>Prostate Cancer and Prostatic Diseases, Published online: 03 February 2026; <a href="https://www.nature.com/articles/s41391-026-01080-0">doi:10.1038/s41391-026-01080-0</a></p>Bridging the gap between PSMA-PET and reality: critical missing elements in AR-guided pelvic lymph node dissection Prostate Cancer Journal February 4, 2026 Original source
Editorial: Advancing external beam radiotherapy—and rediscovering what brachytherapy already provides? <p>Prostate Cancer and Prostatic Diseases, Published online: 04 February 2026; <a href="https://www.nature.com/articles/s41391-026-01084-w">doi:10.1038/s41391-026-01084-w</a></p>Editorial: Advancing external beam radiotherapy—and rediscovering what brachytherapy already provides? Prostate Cancer Journal February 4, 2026 Original source
Targeting RRBP1 reverses immune evasion and enhances immunotherapy efficacy via the CXCL10-CXCR3 axis in bladder cancer Background <p>Crosstalk between inflammation and the immune system plays an important role in tumor malignant progression, immune evasion, and immunotherapy efficacy. This study aims to explore the significance of inflammation-associated gene ribosomal-binding protein 1 (RRBP1) in modulating tumor malignant progression and immune escape.</p> Methods <p>This study was used transcriptome, proteomic and in vivo anti-programmed death-ligand 1 (PD-L1) antibody CRISPR Cas9… Journal for ImmunoTherapy of Cancer February 3, 2026 Original source
Bond with Clinical Team Helps Retiree Through MDS and Stem Cell Transplant <p>Bill Kelley’s unbreakable bond with the clinical team that guided him through myelodysplastic syndrome (MDS), a group of rare blood disorders impacting the bone marrow, and a stem cell transplant was never more evident than during a Sunday night in the summer of 2025. Kelley’s sister Joan had arranged a surprise 70th birthday baseball outing for him and 30 of… Dana-Farber Cancer Institute February 3, 2026 Original source
Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant trials (PATHdata): Results of a Society for Immunotherapy of Cancer multi-institutional reproducibility study Pathologic response is an emerging surrogate marker for therapeutic efficacy and long-term patient outcomes. Updated guidelines for pan-tumor pathologic response assessment have recently been adopted for ongoing clinical trials and routine clinical care. The goal of this study was to prospectively evaluate the interobserver variability amongst pathologists in assessments of treatment response across tumor types, anatomic locations, and specimen types. Annals of Oncology February 3, 2026 Original source
Changing the management of advanced penile cancer Penile squamous cell carcinoma (PSCC) constitutes a rare, yet clinically relevant malignancy, representing approximately 1% of all new cancer cases in males worldwide; a total of 37,700 new cases and 17,000 deaths due to PSCC are expected annually.1 In Europe and in the United States, about 7,000 and 2,000 men are diagnosed with PSCC per year respectively, while in Latin… Annals of Oncology February 3, 2026 Original source
Progress in Targeting the Untouchables: Emerging Approaches for Hard-to-Drug Cancer Targets. Innovation in drug development is an evolving concept that can take many forms, and is often confused with iteration, i.e., new versions of existing drug classes targeting familiar oncogenes. Yet meaningful innovation increasingly lies in translating approaches to historically ‘untouchable’ targets: transcription factors, tumor suppressors, and lineage-defining proteins, which have long resisted conventional pharmacological approaches. At the ESMO Targeted Anticancer… Annals of Oncology February 3, 2026 Original source
The Evolution of Autonomous Diagnostic Workflows in Cancer Imaging Over the past decade, image analysis has changed fundamentally. In radiology and, increasingly, in histopathology, we have moved from hand-crafted features and simple pattern recognition to deep models that extract clinically meaningful information directly from pixels. At the same time, imaging has become even more central to oncology: almost every important diagnostic and therapeutic decision in cancer care involves a… Annals of Oncology February 3, 2026 Original source
Sequential treatment with ruxolitinib and imetelstat effectively depletes myelofibrosis hematopoietic stem and progenitor cells <p>Leukemia, Published online: 03 February 2026; <a href="https://www.nature.com/articles/s41375-026-02871-z">doi:10.1038/s41375-026-02871-z</a></p>Sequential treatment with ruxolitinib and imetelstat effectively depletes myelofibrosis hematopoietic stem and progenitor cells Leukemia Journal February 3, 2026 Original source
Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of <i>CXCR4</i> and <i>TP53</i> alterations <p>Leukemia, Published online: 03 February 2026; <a href="https://www.nature.com/articles/s41375-026-02877-7">doi:10.1038/s41375-026-02877-7</a></p>Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of <i>CXCR4</i> and <i>TP53</i> alterations Leukemia Journal February 3, 2026 Original source
Correction: Reduced expression but not deficiency of <i>GFI1</i> causes a fatal myeloproliferative disease in mice <p>Leukemia, Published online: 03 February 2026; <a href="https://www.nature.com/articles/s41375-026-02879-5">doi:10.1038/s41375-026-02879-5</a></p>Correction: Reduced expression but not deficiency of <i>GFI1</i> causes a fatal myeloproliferative disease in mice Leukemia Journal February 3, 2026 Original source
JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms <p>Leukemia, Published online: 02 February 2026; <a href="https://www.nature.com/articles/s41375-025-02843-9">doi:10.1038/s41375-025-02843-9</a></p>JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms Leukemia Journal February 2, 2026 Original source
Correction: Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8+ T cells Journal for ImmunoTherapy of Cancer February 2, 2026 Original source
Oncolytic virus OH2 induces PD-L1 upregulation via NF-{kappa}B signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system Background <p>Prostate cancer (PCa) is a prevalent malignancy with limited treatment options for advanced stages. Oncolytic virotherapy represents a promising immunotherapeutic approach, but its efficacy and underlying mechanisms in PCa, particularly concerning immune checkpoint regulation, remain unclear.</p> Methods <p>The antitumor effects of the oncolytic virus oncolytic herpes simplex virus type 2 (OH2) were evaluated in PCa cell lines and mouse… Journal for ImmunoTherapy of Cancer February 2, 2026 Original source
Multiomic analysis of colorectal adenocarcinoma reveals a new subtype of myofibroblastic cancer-associated fibroblasts that express high levels of B7-H3 and have poor-prognosis value Background <p>The high mortality rate of patients with colorectal cancer combined with the lack of nontoxic and efficient personalized treatments makes it urgent to develop new targeted therapies for this disease. B7-H3 appears to be a good target, as it is overexpressed in tumor tissue compared with normal tissue. However, B7-H3 is a molecule with ambivalent functions and is expressed… Journal for ImmunoTherapy of Cancer February 2, 2026 Original source
Optimizing anti-PI3K{delta} and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple-negative breast cancer improves outcome by removing treatment-related adverse events Background <p>Current immunotherapy regimens most often fail due to an insufficient T cell response and/or immune-related adverse events (irAEs) which lead to treatment discontinuation. Additionally, many cancers likely require combination immunotherapies which may further increase irAE. This is exemplified in our preclinical models of dual targeting of regulatory T cells with a phosphoinositide 3-kinase (PI3K) inhibitor and antibodies to LAG-3.… Journal for ImmunoTherapy of Cancer February 2, 2026 Original source
Carboplatin trains macrophages for cardiac defence <p>Nature Reviews Cancer, Published online: 29 January 2026; <a href="https://www.nature.com/articles/s41568-026-00911-5">doi:10.1038/s41568-026-00911-5</a></p>In a recent Science Immunology paper, He et al. show that treatment with the chemotherapy carboplatin reshapes cardiac-resident macrophage populations, protecting against later heart disease. Nature Reviews Cancer February 1, 2026 Original source
Radical prostatectomy without prior biopsy: an initial decision-making algorithm based on PSMA PET/mpMRI <p>Prostate Cancer and Prostatic Diseases, Published online: 31 January 2026; <a href="https://www.nature.com/articles/s41391-026-01081-z">doi:10.1038/s41391-026-01081-z</a></p>Radical prostatectomy without prior biopsy: an initial decision-making algorithm based on PSMA PET/mpMRI Prostate Cancer Journal February 1, 2026 Original source